Hemoglobin C trait is a rare blood disorder that affects a small number of people worldwide. It is caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. In this article, we will take a closer look at hemoglobin C trait and explore the potential risks associated with this rare disorder.
Hemoglobin C trait is a genetic condition caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. Hemoglobin C trait is most common in people of African, Mediterranean, and Middle Eastern descent. It is estimated that about 1 in 250 people of African descent have the trait, while about 1 in 500 people of Mediterranean and Middle Eastern descent have the trait.
Hemoglobin C trait is usually diagnosed through a simple blood test. If the test shows that the individual has hemoglobin C trait, they will not need any further treatment. However, it is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder. People with hemoglobin C trait should be monitored for any signs of anemia, which can be caused by a decrease in the number of red blood cells in the body. Anemia can lead to fatigue, shortness of breath, and paleness. If anemia is suspected, a doctor may recommend a blood transfusion to replace the missing red blood cells.
People with hemoglobin C trait are at an increased risk of developing a rare form of anemia called hemolytic anemia. This condition occurs when red blood cells are destroyed faster than they can be replaced, leading to a decrease in the number of red blood cells in the body. Hemolytic anemia can cause fatigue, shortness of breath, paleness, jaundice, and dark urine. If left untreated, this condition can be life-threatening. People with hemoglobin C trait are also at an increased risk of developing gallstones. Gallstones are hardened deposits of bile, a fluid produced by the liver to help digest fat. They can cause pain in the upper right side of the abdomen, nausea, and vomiting. In addition, people with hemoglobin C trait are at an increased risk of developing thalassemia, a group of inherited blood disorders that can cause anemia, fatigue, and other symptoms. Thalassemia can be life-threatening if left untreated.
Hemoglobin C trait is a rare blood disorder caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. It is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder, including an increased risk of hemolytic anemia, gallstones, and thalassemia. If any of these conditions are suspected, a doctor should be consulted for diagnosis and treatment.
1.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
2.
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?
3.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
4.
The pandemic had little impact on mental health symptoms.
5.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
1.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
2.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
3.
Understanding the Rare Disease: Werner Syndrome Explained
4.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
5.
Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation